Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Amplia Therapeutics Limited reports considerable progress in the Phase 2a ACCENT trial for pancreatic cancer, with 24 of 26 patients recruited and promising preliminary results showing a significant therapeutic response. The trial, which assesses the efficacy of their FAK inhibitor in combination with chemotherapy, has received positive data from earlier phases, justifying further development. Financially, Amplia ended the quarter with $4.8 million in cash, having successfully raised additional funds through a shareholder entitlement offer.
For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.
